7,12-Dimethylbenz[a]anthracene
(Synonyms: 9,10-二甲基-1,2-苯并蒽；DMBA) 目录号 : GC46733
7,12-Dimethylbenz[a]anthracene是一种免疫抑制剂，也是一种强效的器官特异性致癌物。
![7,12-Dimethylbenz[a]anthracene Chemical Structure](/media/struct/GC4/GC46733.png "7,12-Dimethylbenz[a]anthracene Chemical Structure")
Cas No.:57-97-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
Cell lines | Normal human epidermal keratinocytes |
Preparation Method | Normal human epidermal keratinocytes were treated with 7,12-Dimethylbenz[a]anthracene 1μM for 4hours. |
Reaction Conditions | 7,12-Dimethylbenz[a]anthracene:1μM; 4hours. |
Applications | 7,12-Dimethylbenz[a]anthracene augmented the expression of CYP1A1 as well as CCL20, p19, and IL-36γ mRNA . There was no significant increase in p40 and IL-36β mRNA expression . |
| Animal experiment [2]: | |
Animal models | Mammary tumor Modle |
Preparation Method | All experiments were performed using female Sprague-Dawley rats. The animals were 50 days old, weighed 140-150g when fed a hydrocarbon diet and were free of respiratory disease. 2 g of 7,12-Dimethylbenzanthracene (DMBA) was dissolved in 100 ml of sesame oil and gently warmed. The solution was dripped into the stomach through a soft rubber catheter and the administration was only once. |
Dosage form | 7,12-Dimethylbenz[a]anthracene: 15, 20mg/each; po;1 time |
Applications | Rats fed 7,12-Dimethylbenz[a]anthracene had detectable tumors within 150 days, sexual cycles occurred every 4-15 days, 7,12-Dimethylbenz[a]anthracene induced cancer and leukopenia, and caused a temporary cessation of body growth, but did not cause a significant decrease in pituitary gonadotropin production or ovarian function. |
References: [1]. Sato Y, Fujimura T, Hidaka T, Lyu C, Tanita K, Matsushita S, Yamamoto M, Aiba S. Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma. Front Immunol. 2020 Oct 16;11:534323. [2]. Huggins C, Grand L C, Brillantes F P. Mammary cancer induced by a single feeding of polynuclear hydrocarbons, and its suppression[J]. Nature, 1961, 189(4760): 204-207. | |
7,12-Dimethylbenz[a]anthracene is an immunosuppressor as well as a potent organ-specific carcinogen.Co-treatment of 7,12‑dimethylbenz[a]anthracene with 12-O-tetradecanoylphorbol-13-acetate (TPA) promotes tumor growth in certain two-stage carcinogenesis models[1].
7,12-Dimethylbenz[a]anthracene (1μM; 4h) increased the expression of CCL20, IL-36γ, and p19 in NHKCs[2]. 7,12-Dimethylbenz[a]anthracene (20μM; 24 and 44h) inhibited the expansion of cumulus cells at 24 hours and promoted the separation of cumulus cells from oocytes at 44 hours,induces sharp ROS rise[3].
7,12-Dimethylbenz[a]anthracene (1mg/kg; po; 6weeks) exposure enhanced the activation of EGFR, ErbB2, Akt, and Erk in the premalignant mammary tissues [4]. After treatment with 7,12-Dimethylbenz[a]anthracene (20μg/ml; 24h), the expression of E-CAD was decreased and the expression of α-SMA was increased in MCF10A cells[5].7,12-Dimethylbenz[a]anthracene (50mg/kg; po; 4weeks) induced elevation in PGE2 levels of tumors [6].
References:
[1].Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res. 2005 Oct 15;65(20):9304-11.
[2].Sato Y, Fujimura T, Hidaka T, Lyu C, Tanita K, Matsushita S, Yamamoto M, Aiba S. Possible Roles of Proinflammatory Signaling in Keratinocytes Through Aryl Hydrocarbon Receptor Ligands for the Development of Squamous Cell Carcinoma. Front Immunol. 2020 Oct 16;11:534323
[3].Song ZQ, Li X, Wang YK, Du ZQ, Yang CX. 7,12-DIMETHYLBENZ[Α]ANTHRACENE acts on cumulus cells to desynchronize nuclear and cytoplasmic maturation of pig oocytes. Sci Rep. 2017 May 10;7(1):1687.
[4].Ma Z, Kim YM, Howard EW, Feng X, Kosanke SD, Yang S, Jiang Y, Parris AB, Cao X, Li S, Yang X. 7,12-DIMETHYLBENZ[Α]ANTHRACENE promotes ErbB2 mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability. Oncol Rep. 2018 Sep;40(3):1632-1640.
[5].Liu G, Lim D, Cai Z, Ding W, Tian Z, Dong C, Zhang F, Guo G, Wang X, Zhou P, Feng Z. The Valproate Mediates Radio-Bidirectional Regulation Through RFWD3-Dependent Ubiquitination on Rad51. Front Oncol. 2021 Mar 25;11:646256.
[6].Karimi B, Ashrafi M, Shomali T, Yektaseresht A. Therapeutic effect of simvastatin on 7,12-DIMETHYLBENZ[Α]ANTHRACENE-induced breast cancer in mice. Fundam Clin Pharmacol. 2019 Feb;33(1):84-93.
7,12-Dimethylbenz[a]anthracene是一种免疫抑制剂，也是一种强效的器官特异性致癌物。在某些两阶段致癌模型中，7,12‑dimethylbenz[a]anthracene与 12-O-十四烷酰佛波醇-13-乙酸酯 (TPA)共同处理可促进肿瘤生长[1]。
7,12-Dimethylbenz[a]anthracene （1μM；4h）可增加 NHKCs 中 CCL20、IL-36γ 和 p19 的表达[2]。7,12-Dimethylbenz[a]anthracene (20μM；24 和 44h) 可在 24 小时时抑制卵丘细胞的扩张，在 44 小时时促进卵丘细胞与卵母细胞的分离，并诱导 ROS 急剧增加[3]。用 7,12-Dimethylbenz[a]anthracene （20μg/ml；24h）处理 MCF10A 细胞可降低 E-CAD 表达并增加 α-SMA 表达[4]。
7,12-Dimethylbenz[a]anthracene（1mg/kg；po；6weeks）暴露可增强癌前乳腺组织中 EGFR、ErbB2、Akt 和 Erk 的活化[5]。7,12-Dimethylbenz[a]anthracene（50mg/kg；po；4weeks）可诱导肿瘤中 PGE2 水平升高 [6]。
| Cas No. | 57-97-6 | SDF | |
| 别名 | 9,10-二甲基-1,2-苯并蒽；DMBA | ||
| Canonical SMILES | CC1=C2C=CC=CC2=C(C)C3=C4C(C=CC=C4)=CC=C13 | ||
| 分子式 | C20H16 | 分子量 | 256.3 |
| 溶解度 | DMF: 20 mg/ml,DMSO: 10 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.9017 mL | 19.5084 mL | 39.0168 mL |
| 5 mM | 0.7803 mL | 3.9017 mL | 7.8034 mL |
| 10 mM | 0.3902 mL | 1.9508 mL | 3.9017 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。